Bayer (BAYN: DE) subsidiary Asklepios BioPharmaceutical (AskBio) has drawn attention to the role of its own adeno-associated virus technology in all US Food and Drug Administration-approved gene therapies of this type.
The statement from the firm follows the recent approval of a one-time hemophilia B treatment, Hemgenix (etranacogene dezaparvovec-drlb), developed by Dutch gene therapy company uniQure (Nasdaq: QURE).
AskBio said the approval “marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio co-founder Jude Samulski.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze